Rocket Pharmaceuticals
RCKT
87 hedge funds and large institutions have $622M invested in Rocket Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 13 reducing their positions, and 16 closing their positions.
162% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
15% more call options, than puts
Call options by funds: $194K | Put options by funds: $169K
4% more funds holding
Funds holding: 84 → 87 (+3)
2.17% more ownership
Funds ownership: 92.77% → 94.94% (+2.2%)
31% less capital invested
Capital invested by funds: $906M → $622M (-$284M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$17.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.6M |
| 3 |
BlackRock
New York
|
+$7.81M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$7.47M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$19.1M |
| 2 |
Morgan Stanley
New York
|
-$2.75M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.66M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.33M |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
-$1.73M |
RCKT Hedge Fund Activity: Q4 2018 in Review
87 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2018, worth a combined $622M — down 31% from $906M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RCKT positions and 16 closed out — a net gain of 4 holders — while 34 added to existing stakes and 13 trimmed.
The largest buyer was RTW Investments, adding an estimated $17.7M. The largest seller was OrbiMed, exiting entirely with an estimated $19.1M sold.
- 87 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2018, up from 84 in Q3 2018.
- Funds reported $622M of Rocket Pharmaceuticals stock for Q4 2018, down 31% quarter-over-quarter.
- 20 funds opened new Rocket Pharmaceuticals positions in Q4 2018 and 16 closed out, a net change of +4 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2018 was RTW Investments, an estimated $17.7M added.
- The largest Rocket Pharmaceuticals seller in Q4 2018 was OrbiMed, an estimated $19.1M sold.
Based on aggregated 13F filings for Q4 2018.